Found 254 clinical trials
Telitacicept in Primary APS Patients
Telitacicept will be added on traditional antithrombotic and immunosuppressive treatment in primary antiphospholipid syndrome (APS) patients with three positive antiphospholipid antibodies (aPL) and at least one extra-criteria manifestations, including thrombocytopenia, autoimmune hemolytic anemia, aPL associated nephropathy, heart valvular disease, non-stroke neurological manifestations.
- 0 views
- 15 Oct, 2021
- 1 location
Rheumatology Patient Registry and Biorepository
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
connective tissue disease
adult onset still's disease
giant cell arteritis
rheumatoid arthritis
psoriatic arthritis
- 0 views
- 05 Aug, 2020